Northwest Biotherapeutics Refutes DCVax-L MAA Rejection Rumors

Northwest Biotherapeutics addressed rumors alleging the rejection of its Marketing Authorization Application (MAA) for DCVax-L for glioblastoma by the Medicines and Healthcare Products Regulatory Agency (MHRA). The company confirmed with the MHRA that the application remains under initial regulatory review, has not been refused or withdrawn, and continues to progress. Northwest Biotherapeutics categorically refutes these false rumors, suggesting they may be linked to stock manipulation following positive Phase 3 trial data.